ADC Therapeutics to Participate in the Jefferies London Healthcare Conference

Rhea-AI Summary

ADC Therapeutics (NYSE: ADCT) announced that CEO Ameet Mallik will participate in a fireside chat at the Jefferies London Healthcare Conference on November 15 at 9:45 a.m. GMT. A live webcast will be available on the company's Investors page, with a replay accessible for 30 days. The company specializes in targeted antibody drug conjugates aimed at improving cancer treatment. Its FDA-approved ADC, ZYNLONTA, is used for treating diffuse large B-cell lymphoma, among other ongoing trials.

LAUSANNE, Switzerland--(BUSINESS WIRE)-- ADC Therapeutics SA (NYSE: ADCT) announced today that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 15^th at 9:45 a.m. GMT.

A live webcast of the presentation will be available via the Events & Presentations page in the Investors section of ADC Therapeutics’ website, ir.adctherapeutics.com. A replay of the webcast will be available for approximately 30 days.

About ADC Therapeutics

ADC Therapeutics (NYSE: ADCT) is a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs). The Company is advancing its proprietary PBD-based ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.

ADC Therapeutics’ CD19-directed ADC ZYNLONTA® (loncastuximab tesirine-lpyl) is approved by the FDA for the treatment of relapsed or refractory diffuse large b-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents. Cami (camidanlumab tesirine) is being evaluated in a pivotal Phase 2 trial for relapsed or refractory Hodgkin lymphoma and in a Phase 1b clinical trial for various advanced solid tumors. In addition to ZYNLONTA and Cami, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development.

ADC Therapeutics is based in Lausanne (Biopôle), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey. For more information, please visit https://adctherapeutics.com/ and follow the Company on Twitter and LinkedIn.

ZYNLONTA® is a registered trademark of ADC Therapeutics SA.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221107005128/en/

Investors

Eugenia Litz

ADC Therapeutics

Eugenia.Litz@adctherapeutics.com

+44 7879 627205



Amanda Loshbaugh

ADC Therapeutics

Amanda.Loshbaugh@adctherapeutics.com

+1 917-288-7023



Media

Mary Ann Ondish

ADC Therapeutics

Maryann.Ondish@adctherapeutics.com

+1 914-552-4625

Source: ADC Therapeutics SA

FAQ

When is ADC Therapeutics' CEO participating in the Jefferies London Healthcare Conference?

Ameet Mallik, CEO of ADC Therapeutics, will participate on November 15 at 9:45 a.m. GMT.

Where can I watch the ADC Therapeutics presentation at the Jefferies London Healthcare Conference?

The presentation will be available live on ADC Therapeutics' Investors page at ir.adctherapeutics.com.

What is ZYNLONTA and its significance for ADC Therapeutics?

ZYNLONTA is an FDA-approved ADC for treating relapsed diffuse large B-cell lymphoma, showcasing ADC Therapeutics' advancements in cancer treatment.

What type of technology does ADC Therapeutics utilize?

ADC Therapeutics utilizes next-generation, targeted antibody drug conjugates (ADCs) for cancer treatment.

What is the purpose of the Jefferies London Healthcare Conference?

The Jefferies London Healthcare Conference serves as a platform for healthcare companies like ADC Therapeutics to discuss advancements and strategies in the industry.